Overall, the potential of sEVs‐PD‐L1+ as an immunosuppressive agent is promising for a wide range of therapeutic applications, including the treatment of disorders such as autoimmune diseases, chronic infections, and inflammation [19]. Here, CD274 is linked to autoimmune disease.